TNGX — Tango Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1819133 ·
Last close
$20.04
Market Cap
$2.90B
52W High
$28.41
52W Low
$10.80
ADV30
3,086,080
Next earnings
2026-08-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -48,769,000 | -45,514,000 | 435,792,000 | 157,828,000 | 44,286,000 |
| Dec 2025 | 0 | — | -41,864,000 | -38,749,000 | 398,690,000 | 112,279,000 | 52,511,000 |
| Sep 2025 | 53,811,000 | — | 14,072,000 | 15,884,000 | 210,136,000 | 58,338,000 | 50,105,000 |
| Jun 2025 | 3,181,000 | — | -40,967,000 | -38,853,000 | 237,890,000 | 39,272,000 | 102,936,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-138,886,000
Investing CF
$-40,865,000
Financing CF
$222,500,000
CapEx
$-1,048,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.87
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-603,152,000
Inventory
—
Receivables
—
ST Investments
$230,859,000
EBIT TTM
$-111,289,000
Pretax Income TTM
$-101,590,000
Interest Exp TTM
—
Analysts
10
Yahoo Snapshot (yfinance, live)
Total Revenue
$56,992,000
EBITDA
$-115,406,000
Free Cash Flow
$-68,235,000
Enterprise Value
$2,580,624,128
Total Cash
$379,839,008
Total Debt
$32,788,000
Shares Out
144,647,982
Trailing EPS
$-0.83
Book Value
$2.55
ROE
-38.4%
ROA
-20.7%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 62,384,000 | -111,289,000 | -101,594,000 | 398,690,000 | 52,511,000 | — | -138,886,000 |
| Dec 2024 | 42,069,000 | -145,595,000 | -130,302,000 | 316,492,000 | 116,975,000 | — | -131,501,000 |
| Dec 2023 | 36,527,000 | -114,173,000 | -101,744,000 | 402,567,000 | 149,459,000 | — | -117,982,000 |
| Dec 2022 | 24,860,000 | -111,071,000 | -108,176,000 | 436,470,000 | 186,994,000 | — | -109,080,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.58
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| GPCR | Structure Therapeutics Inc. | $2.81B | $39.58 | — |
| DYN | Dyne Therapeutics, Inc. | $3.00B | $18.15 | — |
| KLRA | Kailera Therapeutics, Inc. | $2.79B | $21.57 | — |
| SUPN | SUPERNUS PHARMACEUTICALS, INC. | $2.77B | $47.77 | — |
| RCUS | Arcus Biosciences, Inc. | $3.03B | $24.13 | — |
News headlines (Yahoo Finance, 1h cache)
Acuta Capital Sells 56% of Ocular Therapeutix Shares in Q1
2026-05-26 22:26 · Yahoo
A Look At Tango Therapeutics (TNGX) Valuation After Wider Losses And Boardroom Changes
2026-05-22 03:14 · Yahoo
Boxer Capital’s $18 Million Corvus Pharma Bet Signals Confidence in This Biotech’s Next Phase
2026-05-17 20:46 · Yahoo
Why One Healthcare Fund Increased Its Kodiak Sciences Stake Amid an Eye-Popping Rally
2026-05-17 20:17 · Yahoo
Vir Biotechnology Stock Has Doubled This Past Year. One Fund Just Bought 1.2 Million Shares
2026-05-17 20:07 · Yahoo
Acuta Capital Bet on Erasca (ERAS) and Targeted Cancer Treatments With a 354,575 Share Buy
2026-05-16 15:01 · Yahoo
Tango Therapeutics (TNGX) Is Down 10.7% After Pipeline Pivot And Board Changes - Has The Bull Case Changed?
2026-05-16 14:10 · Yahoo
Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights
2026-05-13 20:07 · Yahoo
Stifel Remains Bullish on Tango Therapeutics (TNGX)
2026-05-10 23:13 · Yahoo
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-05-04 20:31 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.